Regorafenib Combined with BRAF/MEK Inhibitors for the Treatment of Refractory Melanoma Brain Metastases
Iris Dirven, Eden Pierre, An-Sofie Vander Mijnsbrugge, Manon Vounckx, Jolien I. Kessels, Bart Neyns · 2024
Read Regorafenib Combined with BRAF/MEK Inhibitors for the Treatment of Refractory Melanoma Brain Metastases by Iris Dirven, Eden Pierre, An-Sofie Vander Mijnsbrugge, Manon Vounckx, Jolien I. Kessels, Bart Neyns (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11640054.txt.
Description
Iris Dirven and five co-authors report a 2024 case series on melanoma that has spread to the brain and no longer yields to standard drugs. Once immune drugs and targeted BRAF and MEK drugs fail, options run out. One further drug, regorafenib, can block a route tumors use to resist the targeted pair.
The team reviewed 22 patients treated at one center with regorafenib added to the targeted drugs, on a compassionate basis. Most had the BRAF form of the disease and were getting worse when the add-on began. High blood pressure and rash were the main strong side effects seen in the group.
Catalog record
| CREATOR | Iris Dirven, Eden Pierre, An-Sofie Vander Mijnsbrugge, Manon Vounckx, Jolien I. Kessels, Bart Neyns |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |